To include your compound in the COVID-19 Resource Center, submit it here.

CAFC biosimilars ruling focuses eyes on SCOTUS

A federal court's decision reaffirming that biosimilars cannot be launched until 180 days after FDA approval is focusing renewed attention

Read the full 204 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE